The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.
The WHO prequalification confirms that the products meet WHO standards for quality, safety, and performance.
Even without a booster, the vaccine triggered mucosal and systemic immunity, which other intranasal recombinant H5 flu vaccines have not achieved in clinical trials.
The revamped open-access site tracks scientific progress toward the development of broadly protective coronavirus vaccines.
CIDRAP Director Michael Osterholm and co-author Mark Olshaker's new book examines the lessons learned from the COVID-19 pandemic and how a pandemic caused by an even deadlier virus might play out.
Buoyed by promising clinical findings, Moderna says it will explore alternatives for late-stage development of the H5 vaccine.
The next steps include fleshing out mechanisms for benefit sharing, financing, and supply chain logistics.
The group also recommended two vaccine strains for pandemic preparedness, one for the H5N1 2.3.2.1a clade and another targeting the reemerging H5N6 2.3.4.4h clade.
The authors estimate the cost of narrowing the oxygen gap at $34 billion over the next 5 years but called it a highly cost-effective investment with far-reaching effects.
But HHS and other organizations have taken actions to alleviate the shortages, which began with the 2008-2009 recession.
